Overview

A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The study is designed to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of AZD1722 in healthy volunteers taking Renvela.
Phase:
Phase 1
Details
Lead Sponsor:
Ardelyx
Collaborator:
AstraZeneca
Treatments:
Sevelamer